Die Therapie der chronischen Hepatitis-C-Virusinfektion hat sich mit der Zulassung mehrerer neuartiger Substanzen, welche die Virusvermehrung direkt blockieren, grundlegend verändert. Mit der Zulassung dieser direkt antiviral wirkenden Substanzen ist die Therapie nicht nur deutlich einfacher, kürzer und nebenwirkungsärmer, sondern mit Heilungsraten über 90% auch effektiver geworden.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42
Davis GL, Alter MJ, El-Serag H et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–21
Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol. 2014;20:11095–115
van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93
Sarrazin C, Berg T, Ross RS et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol. 2010;48:289–351
Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87
Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65
Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al.; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21
Kowdley KV, Gordon SC, Reddy KR et al.; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88
Ferenci P, Bernstein D, Lalezari J et al.; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92
Manns MP, Foster GR, Rockstroh JK et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov. 2007;6:991–1000
Zeuzem S, Dusheiko GM, Salupere R et al.; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001
van der Meer AJ, Hansen BE, Fattovich G et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut. 2015;64:322–31
ClinicalTrials.govIdentifier: NCT 02201940
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grüner, N., Gerbes, A. Direkter Angriff auf das Hepatitis-C-Virus. MMW - Fortschritte der Medizin 157, 57–60 (2015). https://doi.org/10.1007/s15006-015-3035-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-015-3035-0